Establishment Labs Holdings Inc. - 10-Q Summary (Q2 2026)
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Establishment Labs Holdings Inc. is a global medical device company manufacturing and marketing silicone gel-filled breast implants, primarily under the Motiva Implants brand. The company operates manufacturing facilities in Costa Rica and sells products in the U.S., Europe, Latin America, Asia, and the Middle East. The company is a large accelerated filer and is not a shell company.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Revenue | $67.5 million | $127.4 million |
| Gross Profit | $47.7 million | $90.0 million |
| Gross Margin | 70.6% | 70.7% |
| Net Loss | $(11.7) million | $(25.1) million |
| Loss Per Share (Basic/Diluted) | $(0.39) | $(0.84) |
| Cash and Cash Equivalents | $71.2 million (as of June 30, 2026) | N/A |
| Total Debt (Net Carrying Value) | $261.7 million | N/A |
| Operating Cash Flow | N/A | $(20.9) million used |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 31.7% year-over-year for the quarter and 37.5% for the six-month period. This was driven by a $14.4 million increase in U.S. sales (quarterly) and a $27.9 million increase (six-month), alongside growth in international markets.
- Profitability: While the company remains unprofitable, the net loss narrowed significantly. The six-month net loss decreased from $37.3 million in 2025 to $25.1 million in 2026. Operating loss improved from $(31.1) million to $(10.8) million for the six-month period.
- Gross Margin Expansion: Gross margin improved to 70.6% (Q2) and 70.7% (YTD) compared to 68.8% and 68.1% in the prior year periods, attributed to a favorable geographic sales mix and higher U.S. selling prices.
- Debt Restructuring: In April 2026, the company entered an Amended Credit Agreement, borrowing $265 million to repay prior obligations. This increased interest expense to $7.0 million for the quarter (from $6.0 million) and $14.1 million for the six months (from $11.8 million).
Outlook, Risks, and Management Commentary
- Liquidity: Management believes available cash ($71.2 million) and cash from operations are sufficient to meet liquidity requirements for at least the next 12 months. The new credit facility includes a minimum liquidity covenant of $30 million.
- Guidance: The filing does not provide specific numerical guidance for future periods. Management notes that results for the interim period are not necessarily indicative of full-year results.
- Risks: Key risks include ongoing patent litigation in Brazil, Belgium, and the UK regarding SmoothSilk surface architecture; potential product liability claims; reliance on a single-source supplier for raw materials; and exposure to foreign currency fluctuations (Euro and Brazilian Real).
- Unusual Items: The company recorded a $4.8 million settlement in April 2026 for contingent consideration related to a 2024 acquisition. Foreign currency fluctuations resulted in a transaction loss of $0.7 million for the quarter, compared to income in the prior year.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the new Amended Credit Agreement's minimum gross sales and liquidity covenants.
- Patent Litigation Status: Monitor the outcomes of pending infringement and validity challenges in Brazil, Belgium, and the UK, which could impact IP protection and legal costs.
- U.S. Market Penetration: Assess the sustainability of the significant revenue growth in the U.S. market following FDA approval in late 2024.
- Interest Expense Trajectory: Review the impact of the new debt structure, including the potential for Pay-In-Kind (PIK) interest, on future leverage and cash flow.
- Inventory Levels: Note the increase in inventory obsolescence reserves mentioned as a partial offset to margin improvements.